The British Business Bank has made a £100million cornerstone commitment to Apposite Healthcare Growth I, a new fund aimed at supporting the expansion of UK-based health technology companies. The move represents the Bank’s largest fund commitment to date, as well as its first investment with specialist healthcare and life sciences investor Apposite Capital. The scale-up capital shortage Apposite Healthcare Growth I will focus on backing innovative businesses operating across a range of critical sub-sectors, including: Medical products. Diagnostics. Life sciences tools. Digital health. Pharmaceutical outsourcing services. The new fund was launched to directly address the ongoing shortage of scale-up capital available for UK life sciences companies that are approaching a critical growth inflection point. By investing in companies developing market-leading technologies and services designed to improve patient outcomes, the fund aims to help these businesses compete globally and create highly skilled domestic jobs. Bridging the funding gap The £100 million anchor investment aligns closely with the British Business Bank’s broader strategy to create deeper pools of scale-up funding. As the largest investor in UK venture and venture growth capital funds, the Bank frequently makes cornerstone commitments to help funds achieve a successful first close, providing them with the necessary scale to execute their investment strategies effectively. Currently, the British Business Bank intends to deliver a major step change in its support for UK scale-ups, actively targeting over 60 per cent of its venture and growth investment flow toward this crucial business stage. The institution also aims to support the launch…
Want more insights? Join Grow With Caliber - our career elevating newsletter and get our take on the future of work delivered weekly.
